{
    "id": 1398,
    "fullName": "CCNE1 amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "CCNE1 amplification indicates an increased number of copies of the CCNE1 gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 898,
        "geneSymbol": "CCNE1",
        "terms": [
            "CCNE1",
            "CCNE",
            "pCCNE1"
        ]
    },
    "variant": "amp",
    "createDate": "08/12/2014",
    "updateDate": "12/11/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 21290,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to Barasertib (AZD1152), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21289,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to AT7519, demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CCNE1 amplification was associated with acquired resistance to Ibrance (palbociclib) in an estrogen-receptor positive breast cancer cell line in culture (PMID: 27020857).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 60075,
                "name": "estrogen-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5181,
                    "pubMedId": 27020857,
                    "title": "Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27020857"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21288,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to Ibrance (palbociclib), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2222,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PHA-533533 inhibited phosphorylation of RB1 and induced apoptosis in ovarian cancer cells with CCNE1 amplification (PMID: 24004674).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 2721,
                "therapyName": "PHA-533533",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2783,
                    "pubMedId": 24004674,
                    "title": "Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24004674"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2223,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Dinaciclib (SCH 727965) inhibited phosphorylation of Rb1 and induced apoptosis in ovarian cancer cells with CCNE1 amplification (PMID: 24004674).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2783,
                    "pubMedId": 24004674,
                    "title": "Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24004674"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21287,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to Dinaciclib (SCH 727965), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7148,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an ERBB2 (HER2) positive breast cancer cell line harboring CCNE1 amplification demonstrated sensitivity to treatment with Seliciclib in culture (AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 22).",
            "molecularProfile": {
                "id": 24499,
                "profileName": "CCNE1 amp ERBB2 pos"
            },
            "therapy": {
                "id": 1129,
                "therapyName": "Seliciclib",
                "synonyms": null
            },
            "indication": {
                "id": 60079,
                "name": "Her2-receptor positive breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6108,
                    "pubMedId": null,
                    "title": "Abstract 22: Cyclin E amplification, a novel mechanism of resistance to trastuzumab in HER2 amplified breast cancer",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/22"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13944,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, CCNE1 amplification was associated with decreased response to Tykerb (lapatinib), Xeloda (capecitabine), and Eloxatin (oxaliplatin) combination treatment (66.7% of non-responders vs 22.2% of responders, p=0.08) in patients with Erbb2 (Her2)-positive (defined as IHC3+ or IHC 2+ with ERBB2 amplification) gastric adenocarcinoma (PMID: 29409051; NCT02015169).",
            "molecularProfile": {
                "id": 29891,
                "profileName": "CCNE1 amp ERBB2 over exp"
            },
            "therapy": {
                "id": 1498,
                "therapyName": "Capecitabine + Lapatinib + Oxaliplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11372,
                    "pubMedId": 29409051,
                    "title": "Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29409051"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 16190,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, a patient with recurrent high-grade serous ovarian cancer harboring a TP53 I195T mutation and amplifications of ERBB2, CCNE1, PIK3CA, and SMARCA4 was treated with combined Taxol (paclitaxel) and Mektovi (binimetinib) therapy for approximately seven months, followed by Mektovi (binimetinib) alone for two months, and was progression-free at four years post-therapy (PMID: 29844129; NCT01649336).",
            "molecularProfile": {
                "id": 31513,
                "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T"
            },
            "therapy": {
                "id": 2010,
                "therapyName": "Binimetinib + Paclitaxel",
                "synonyms": null
            },
            "indication": {
                "id": 2152,
                "name": "ovary epithelial cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14290,
                    "pubMedId": 29844129,
                    "title": "Phase Ib Study of Binimetinib with Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer: Final Results, Potential Biomarkers, and Extreme Responders.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29844129"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19471,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination treatment synergistically inhibited tumor growth in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8901,
                "therapyName": "AZD7648 + Pegylated liposomal-doxorubicin",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19472,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 treatment inhibited tumor growth, however, with decreased response compared to AZD7648 and Doxil (pegylated liposomal-doxorubicin) combination in a patient-derived xenograft (PDX) model of triple-negative breast cancer harboring TP53 and BRCA2 mutations, CCNE1 amplification, CDKN2A deletion, and wild-type ATM (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8900,
                "therapyName": "AZD7648",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 19481,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD7648 and Lynparza (olaparib) combination treatment inhibited viability of triple-negative breast cancer cells harboring wild-type ATM in culture, and induced tumor regression in a patient-derived xenograft (PDX) model harboring wild-type ATM, TP53 and BRCA2 mutations, CCNE1 amplification, and CDKN2A deletion (PMID: 31699977).",
            "molecularProfile": {
                "id": 34749,
                "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut"
            },
            "therapy": {
                "id": 8902,
                "therapyName": "AZD7648 + Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16922,
                    "pubMedId": 31699977,
                    "title": "AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31699977"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1421,
            "profileName": "CCNE1 amp",
            "profileTreatmentApproaches": [
                {
                    "id": 4836,
                    "name": "CDK2 Inhibitor",
                    "profileName": "CCNE1 amp"
                }
            ]
        },
        {
            "id": 21977,
            "profileName": "CCNE1 amp RB1 loss",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 24499,
            "profileName": "CCNE1 amp ERBB2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29891,
            "profileName": "CCNE1 amp ERBB2 over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31513,
            "profileName": "CCNE1 amp ERBB2 amp PIK3CA amp SMARCA4 amp TP53 I195T",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34553,
            "profileName": "ATM wild-type BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34749,
            "profileName": "BRCA2 mut CCNE1 amp CDKN2A del TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}